Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S2UG
|
|||
| Former ID |
DIB004250
|
|||
| Drug Name |
Selegiline
|
|||
| Synonyms |
selegiline; L-Deprenalin; Emsam; (-)-selegiline; Selegilinum; Selegilina; Carbex; 14611-51-9; Selegilinum [INN-Latin]; Selegilina [INN-Spanish]; UNII-2K1V7GP655; l-E 250; CHEMBL972; CHEBI:9086; N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine; 2K1V7GP655; (R)-(-)-N,alpha-Dimethyl-N-2-propinylphenethylamine; Benzeneethanamine, N,alpha-dimethyl-N-2-propynyl-, (R)-; selgene; (R)-(-)-N-Methyl-N-(1-phenyl-2-propyl)-2-propinylamin; Selegyline; Zalapar; Selegiline (transdermal, Parkinson's/depression); Zunrisa/Rezonic
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2] | Approved | [1], [2] | |
| Skin imperfections [ICD-11: EK71; ICD-10: L91.8] | Patented | [3] | ||
| Chemotherapy-induced nausea [ICD-11: MD90; ICD-10: R11] | Discontinued in Phase 3 | [4] | ||
| Company |
Syntropharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H17N
|
|||
| Canonical SMILES |
CC(CC1=CC=CC=C1)N(C)CC#C
|
|||
| InChI |
1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1
|
|||
| InChIKey |
MEZLKOACVSPNER-GFCCVEGCSA-N
|
|||
| CAS Number |
CAS 14611-51-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9454, 7980587, 8169367, 11113910, 11466580, 11467700, 11486280, 14772861, 14797266, 17397820, 26752066, 29293584, 46509459, 47662432, 47810884, 48259382, 48259383, 48334634, 48416534, 49698549, 49880108, 50104720, 50104721, 50139277, 53789537, 57310317, 61127936, 80766630, 85787938, 85788262, 89449661, 92308745, 92310005, 94569169, 99300917, 103252336, 104298196, 104829538, 117391911, 117884350, 128586172, 134337870, 134339187, 134989154, 137001242, 142170639, 160964372, 175267457, 176484098, 176484773
|
|||
| ChEBI ID |
CHEBI:9086
|
|||
| ADReCS Drug ID | BADD_D02002 | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6639). | |||
| REF 2 | ClinicalTrials.gov (NCT00640159) Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease. U.S. National Institutes of Health. | |||
| REF 3 | Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. | |||
| REF 4 | Clinical pipeline report, company report or official report of GlaxoSmithKline. | |||
| REF 5 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490). | |||
| REF 6 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.